NZ293542A - Treatment of bowel microflora to relive neurological disorders - Google Patents

Treatment of bowel microflora to relive neurological disorders

Info

Publication number
NZ293542A
NZ293542A NZ293542A NZ29354295A NZ293542A NZ 293542 A NZ293542 A NZ 293542A NZ 293542 A NZ293542 A NZ 293542A NZ 29354295 A NZ29354295 A NZ 29354295A NZ 293542 A NZ293542 A NZ 293542A
Authority
NZ
New Zealand
Prior art keywords
treatment
microorganisms
infusion
adjuvants
medicaments
Prior art date
Application number
NZ293542A
Inventor
Thomas Julius Borody
Richard Brown
Original Assignee
Blackmores Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blackmores Ltd filed Critical Blackmores Ltd
Publication of NZ293542A publication Critical patent/NZ293542A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are medicaments containing at least one whole live or dead enteric microorganisms or cell wall containing fragments of the microorganisms in association with one or more pharmaceutically acceptable carriers, excipients and/or adjuvants for use in the treatment of sleep disorders, for inducing sleep or for the treatment of SIDS, for the treatment of children's Cl. Botulinum poisoning in mammals, for the treatment of neuropsychiatric disorder and for the treatment of Chronic Fatigue Syndrome. Preferred microorganisms to be used include Bacteroides, Fifidobacterium, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anerobic cocci, Rumincoccus, Escherichia, Gemmiger, Clostridium or Desulfomonas genera or species. Preferred adjuvants are gastric suppressants, H2-receptor antagonists or proton pump inhibitors. Medicaments are suitably in the form to be administered by colonoscopic infusion, enema, or infusion into the small bowel via an endoscope or by intubation.
NZ293542A 1994-10-07 1995-10-06 Treatment of bowel microflora to relive neurological disorders NZ293542A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM8648A AUPM864894A0 (en) 1994-10-07 1994-10-07 Treatment of bowel-dependent neurological disorders

Publications (1)

Publication Number Publication Date
NZ293542A true NZ293542A (en) 2000-12-22

Family

ID=3783167

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ293542A NZ293542A (en) 1994-10-07 1995-10-06 Treatment of bowel microflora to relive neurological disorders

Country Status (3)

Country Link
AU (1) AUPM864894A0 (en)
NZ (1) NZ293542A (en)
WO (1) WO1996011014A1 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE507696C2 (en) 1996-03-20 1998-07-06 Lars Wiklund Use of a physiologically harmless ammonium compound and / or urea for the prophylaxis of sudden infant death and ways of diagnosing the risk of sudden infant death
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
CA2273848C (en) * 1996-12-18 2008-02-19 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
SE9604844D0 (en) 1996-12-30 1996-12-30 Carl Gerhard Gottfries Agents for the therapeutic treatment of fibromyalgia and chronic fatigue syndrome
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
AU750136B2 (en) * 1997-06-03 2002-07-11 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6444203B2 (en) * 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
FR2808689B1 (en) * 2000-05-11 2004-09-03 Agronomique Inst Nat Rech USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
LT2211626T (en) 2007-08-29 2019-11-11 Ganeden Biotech Inc Baked goods
WO2009055362A1 (en) 2007-10-26 2009-04-30 Moore Brenda E Probiotic compositions and methods for inducing and supporting weight loss
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
DK2348888T3 (en) 2008-10-16 2016-09-12 Ganeden Biotech Inc PROBIOTIC CORN-BASED COMPOSITIONS
AU2009319257B2 (en) * 2008-11-03 2014-10-09 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
AU2014221272B2 (en) * 2008-11-03 2016-01-21 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
US8568743B2 (en) 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
ES2730828T3 (en) 2010-02-01 2019-11-12 Rebiotix Inc Bacteriotherapy for Clostridium difficile colitis
WO2011151941A1 (en) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition having activity of inducing proliferation or accumulation of regulatory t cell
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP3072524B1 (en) * 2010-10-07 2018-01-17 California Institute Of Technology Probiotic therapies for autism
BR112013014827A2 (en) 2010-12-13 2016-10-04 Antony Wettstein gastric and colonic formulations and methods for producing and using the same
BR112013022927A2 (en) 2011-03-09 2016-12-06 Univ Minnesota composition, methods for replacing or supplementing or modifying a subject's microbiota of the colon, and for treating a subject, and, use of a composition
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2877163B1 (en) 2012-07-27 2019-03-20 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
CN114949001A (en) 2012-08-29 2022-08-30 加州理工学院 Diagnosis and treatment of autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
JP6427278B2 (en) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ pirin polypeptide and immune modulation
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
ES2909456T3 (en) 2015-05-22 2022-05-06 Univ Arizona State Methods to treat autism spectrum disorder and associated symptoms
WO2016201114A1 (en) 2015-06-09 2016-12-15 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
RS59446B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
CN114984057A (en) 2015-06-15 2022-09-02 4D制药研究有限公司 Compositions comprising bacterial strains
SI3360559T1 (en) 2015-06-15 2020-02-28 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
NZ745678A (en) 2016-03-04 2019-03-29 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3624782A4 (en) 2017-05-15 2021-05-05 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
AU2018272291A1 (en) 2017-05-22 2020-01-16 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (en) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 Composition comprising a bacterial strain
JP2020521760A (en) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー Lyophilized compositions containing fecal microbial-based therapeutic agents and methods of making and using same
HUE052319T2 (en) 2017-06-14 2021-04-28 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2917415T3 (en) 2017-06-14 2022-07-08 4D Pharma Res Ltd Compositions comprising a bacterial strain
CN111107859B (en) 2017-06-14 2022-04-29 4D制药研究有限公司 Compositions comprising bacterial strains
CN111328284A (en) 2017-08-07 2020-06-23 芬奇治疗公司 Compositions and methods for maintaining and restoring a healthy intestinal barrier
WO2019087842A1 (en) * 2017-11-01 2019-05-09 ビオフェルミン製薬株式会社 Agent for preventing or treating small intestinal disorder induced by nonsteroidal anti-inflammatory drug and proton pump inhibitor
WO2019087841A1 (en) * 2017-11-01 2019-05-09 ビオフェルミン製薬株式会社 AGENT FOR PREVENTING OR TREATING SMALL INTESTINAL DISORDER INDUCED BY CERTAIN NSAIDs AND PPI
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640349B2 (en) * 1988-08-02 1993-08-26 Borody, Thomas J Dr Treatment of gastro-intestinal disorders

Also Published As

Publication number Publication date
WO1996011014A1 (en) 1996-04-18
AUPM864894A0 (en) 1994-11-03

Similar Documents

Publication Publication Date Title
NZ293542A (en) Treatment of bowel microflora to relive neurological disorders
OA09144A (en) Improved interferon therapy.
GR76810B (en)
ZA962369B (en) Pharmaceutical composition and method
TW250435B (en)
Weiming et al. Effect of recombinant human growth hormone and enteral nutrition on short bowel syndrome
SE9800550D0 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
LV11103A (en) Oral administered form of form central nervous system dofamina deficiency states
Holdsworth et al. Pathophysiology of post-gastrectomy hypoglycaemia
NO993600L (en) Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate
EP0957925A4 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
NO975136L (en) A pharmaceutical composition comprising Lactobacillus plantarum and arginine
Tome et al. Primer dosing of S. typhimurium A1-R potentiates tumor-targeting and efficacy in immunocompetent mice
Tremolaterra et al. Intestinal tone and gas motion
Ingelfinger et al. The effect of atropine upon the absorption of vitamin A
EP1450850A4 (en) Method of administering a thymosin alpha 1 peptide
Elamin Use of probiotics for treatment of chemotherapy-induced diarrhea: is it a myth?
Layec et al. Hydration by colonic enteroclysis: An alternative to parenteral hydration in patients with high‐output double enterostomy
Humphries et al. Serum gastrin concentrations following oral bethanechol with and without a meal
Gi-Young et al. Oral Administration of Proteoglycan Isolated from Phellinus linteus in the Prevention and Treatment of Collagen-Induced Arthritis in Mice
Francois et al. Continuous intrathecal baclofen in tetanus. An alternative management.
林迎春 OBSERVATION OF THERAPEUTIC EFFECTS OF ACUPUNCTURE TREATMENT IN 170 CASES OF INFANTILE DIARRHEA
彭悦 et al. 65 CASES OF URINARY TRACT INFECTION TREATED BY TOTAL ACID OF ACHILLEA ALPINA
Salkar et al. Role of Abana in hypertension
D’Ovidio et al. Induratio Penis Plastica: Laser-Chemo-Therapeutic Treatment

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired